id: NEW:buprenorphine_naloxone_combination_treatment_to_small_for_gestational_age_sga
name: Buprenorphine-Naloxone Combination Treatment During Pregnancy â†’ Small for Gestational Age (SGA)
from_node:
  node_id: NEW:buprenorphine_naloxone_combination_treatment
  node_name: Buprenorphine-Naloxone Combination Treatment During Pregnancy
to_node:
  node_id: small_for_gestational_age_sga
  node_name: Small for Gestational Age (SGA)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Pregnant individuals with OUD receive buprenorphine-naloxone combination treatment'
- 'Step 2: Stable medication treatment supports improved maternal health and nutrition during pregnancy'
- 'Step 3: Reduced illicit opioid use and associated lifestyle factors that impair fetal growth'
- 'Step 4: Improved placental function and fetal nutrient delivery'
- 'Step 5: Lower rates of growth-restricted infants at birth'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Loreen Straub et al. 2024. "Comparative Safety of In Utero Exposure to Buprenorphine
    Combined With Naloxone vs Buprenorphine Alone.." https://doi.org/10.1001/jama.2024.11501
  supporting_citations:
  - Additional citations require full-text access - Abstract references limited perinatal safety data
    on combination product
  - Additional citations require full-text access - Study builds on existing buprenorphine monotherapy
    pregnancy research
  - Additional citations require full-text access - Medicaid utilization data from 2000-2018 analyzed
  doi: 10.1001/jama.2024.11501
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Prenatal buprenorphine-naloxone exposure was associated with a 14% lower risk of small for
  gestational age births compared to buprenorphine alone (absolute risk 10.0% vs 12.4%).
quantitative_effects:
  effect_size:
    value: 0.86
    type: relative_risk
    ci_lower: 0.75
    ci_upper: 0.98
  sample_size: 8695
structural_competency:
  equity_implications: Small for gestational age is associated with long-term developmental and health
    consequences. Having flexible treatment options for pregnant individuals with OUD supports structural
    efforts to improve birth outcomes in this high-risk population. Treatment flexibility removes barriers
    that may lead to treatment discontinuation.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.686122'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
